罗沙司他结合静脉补铁治疗血液透析患者肾性贫血的效果研究

Effect of Rosustat Combined with Intravenous Iron Supplement on Renal Anemia in Hemodialysis Patients

目的:探讨罗沙司他结合静脉补铁对血液透析患者肾性贫血的治疗效果及对铁代谢指标的影响。方法:采用随机数字表法将2020年2月—2021年2月本院收治的94例肾性贫血患者分为对照组、观察组,每组47例。对照组予以静脉补铁治疗,观察组予以罗沙司他+静脉补铁治疗,比较两组总体疗效,铁代谢指标及用药安全性。结果:观察组总有效率为95.74%,高于对照组的80.85%(P<0.05);两组治疗后血清铁、血清总铁结合力、血清铁蛋白优于治疗前,且观察组优于对照组(P<0.05);观察组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论:罗沙司他结合静脉补铁治疗血液透析患者肾性贫血的效果确切,能促进铁代谢指标恢复,且具有较高安全性。

Objective: To investigate the therapeutic effect of rosastat combined with intravenous iron supplementation on renal anemia in hemodialysis patients and its effect on iron metabolism indexes. Methods: A total of 94 patients with renal anemia admitted to our hospital from February 2020 to February 2021 were divided into control group and observation group by random number table method, 47 cases in each group. The control group was treated with intravenous iron supplementation, and the observation group was treated with rosastat + intravenous iron supplementation. The overall efficacy, iron metabolism index and medication safety of the two groups were compared. Results: The total effective rate of the observation group was 95.74%, which was higher than 80.85% of the control group(P<0.05). After treatment, serum iron, serum total iron binding capacity and serum ferritin in the two groups were better than those before treatment, and those in the observation group were better than the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P>0.05). Conclusion: Rosuvastatin combined with intravenous iron supplementation is effective in the treatment of renal anemia in hemodialysis patients. It can promote the recovery of iron metabolism and has high safety.